EyePoint Pharmaceuticals announces the completion of enrollment in its Phase 1 clinical trial of EYP-1901 as a potential treatment targeting wet age-related macular degeneration (wet AMD).
FREMONT, CA: EyePoint Pharmaceuticals, Inc., a pharmaceutical organization dedicated to developing and commercializing therapeutics to help enhance the lives of patients suffering from severe eye disorders, has announced that patient enrollment in its Phase 1 clinical trial of EYP-1901 as a prospective twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD) had been completed.
"We are pleased to report the completion of enrollment of all three dose cohorts in our ongoing Phase 1 trial of EYP-1901," said Nancy Lurker, CEO of EyePoint Pharmaceuticals. "EYP-1901 represents an exciting potential advancement for the treatment of wet AMD as a twice-yearly therapy using our proven Durasert® technology that provides reliable, sustained, controlled, and consistent zero-order kinetics delivery. The completion of enrollment of our Phase 1 trial continues to make us confident that the potential advantages of EYP-1901 are obvious to patients and providers. We remain on track to provide interim data from the trial in the fourth quarter of 2021. We would like to thank our investigators and our internal team for making this enrollment possible and for their continued confidence in EYP-1901."
The current Phase 1 DAVIO trial for EYP-1901 is a twelve-month open-label dose-escalation trial analyzing wet AMD patients who responded to the previous anti-VEGF therapies. The principal endpoint of the test is safety, with alterations in best-corrected visual acuity (BCVA) and central subfield thickness as crucial secondary endpoints. EYP-1901 is administered in the doctor's office through a single intravitreal injection. The Company expects that six-month interim data will also include preliminary safety and efficacy assessments.
EyePoint Pharmaceuticals, Inc. is a pharmaceutical organization dedicated to developing and commercializing therapeutics to assist patients with severe eye disorders to live better lives. The pipeline of EYP-1901, a prospective twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration, is based on the Company's proprietary Durasert technology for sustained intraocular drug delivery. The organization has two commercial products: YUTIQ, which is used to treat chronic non-infectious uveitis of the posterior segment of the eye, and DEXYCU, which is used to cure postoperative inflammation after ocular surgery.